Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $36,782.96 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 31,172 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $1.18, for a total value of $36,782.96. Following the transaction, the director owned 3,712,352 shares of the company’s stock, valued at $4,380,575.36. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Luke Evnin also recently made the following trade(s):

• On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total transaction of $28,450.09.
• On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $40,832.52.
• On Friday, November 7th, Luke Evnin sold 43,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total transaction of $48,784.50.
• On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total transaction of $42,285.87.
• On Wednesday, November 5th, Luke Evnin sold 30,774 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $37,544.28.
• On Tuesday, November 4th, Luke Evnin sold 90,164 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total transaction of $110,000.08.
• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $77,876.01.
• On Friday, October 31st, Luke Evnin sold 73,192 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total value of $93,685.76.
• On Thursday, October 30th, Luke Evnin sold 55,795 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total value of $79,786.85.
• On Wednesday, October 29th, Luke Evnin sold 86,154 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total value of $133,538.70.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock opened at $0.92 on Friday. The stock has a market cap of $44.57 million, a price-to-earnings ratio of -0.57 and a beta of 0.72. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The stock has a 50 day moving average price of $1.57 and a 200-day moving average price of $1.33. Werewolf Therapeutics, Inc. has a one year low of $0.60 and a one year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. Equities analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the period. Bridgeway Capital Management LLC boosted its holdings in shares of Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after purchasing an additional 62,414 shares during the period. Bank of America Corp DE grew its stake in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares in the last quarter. Jane Street Group LLC purchased a new position in Werewolf Therapeutics during the 2nd quarter worth $409,000. Finally, Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at $48,000. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday. JMP Securities dropped their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, Bank of America decreased their price target on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Werewolf Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.